COB Columbia Laboratories

Columbia Laboratories to Move to NASDAQ National Market System February 13 First Trading Day on Exchange Under New Symbol CBRX LIVINGSTON, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Columbia Laboratories today announced that its application to list its Common Stock on the NASDAQ National Market has been approved. The Company anticipates that it will begin trading on NASDAQ on Feb. 13, 2004, under the symbol "CBRX." Columbia's Common Stock is expected to continue trading on the American Stock Exchange under the symbol "COB" through Feb. 12, 2004. "We are very pleased to be moving to NASDAQ, the premier stock market for life sciences companies," said Fred Wilkinson, Columbia's president and chief executive officer. "Our listing marks another significant milestone in the evolution of Columbia, and NASDAQ will provide the Company with improved liquidity as well as increased visibility to healthcare investors." Columbia Laboratories has traded on the AMEX since October, 1989. "Columbia has been extremely pleased with the professionalism of the AMEX and thank them, as well as our specialist, HBH Specialists, for their excellent service," added Wilkinson. Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to research and development of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia has introduced Striant(R) (testosterone buccal system) for treatment of hypogonadism in men. Columbia's products primarily utilize the company's patented Bioadhesive Delivery System (BDS) technology. For more information, please visit http://www.columbialabs.com/. This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the successful launch and marketing of Striant(R), the impact of competitive products and pricing; success in obtaining acceptance and approval ofnew products by FDA and international regulatory agencies; competitive economic and regulatory factors in the pharmaceutical and health care industry, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statements. DATASOURCE: Columbia Laboratories, Inc. CONTACT: Ritu Baral, of The Trout Group, +1-212-477-9007, ext. 25, for Columbia Laboratories, Inc.; or Jim Apostolakis, Vice Chairman, +1-212-588-1900, or David Weinberg, Chief Financial Officer, +1-973-994-3999, both of Columbia Laboratories, Inc. Web site: http://www.columbialabs.com/

Copyright